Imugene (ASX:IMU) is an immuno-oncology focused biopharmaceutical company developing HER-2+ gastric and breast cancer immunotherapies. Our mission is to build a pipeline of B-cell peptide cancer vaccines.

Media Releases

Imugene Enhances Portfolio with Compelling Oncolytic Virus (ASX:IMU)

Jul 2019 09:49 AM

Imugene Enhances Portfolio with Compelling Oncolytic Virus from City of Hope, a Cancer Centre in Los Angeles, California FDA Investigational New Drug (IND) package Worldwide, exclusive...read more
Imugene Announce New HER-Vaxx Cancer Vaccine trial data presented at ESMO GI (ASX:IMU)

Jul 2019 09:32 AM

New HER-Vaxx Cancer Vaccine trial data presented at the European Society of Medical Oncology World Congress on Gastrointestinal Cancer SYDNEY, Australia, 8 July 2019: Imugene Limited (ASX:IMU), a c...read more
Imugene announces Updated Phase 1b HER-Vaxx data presented at ASCO (ASX:IMU)

Jun 2019 03:42 PM

SYDNEY, Australia, 4 June 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced positive data from the ongoing patients in the Phase Ib study of its HER-Vaxx cance...read more
Imugene announces Updated Phase Ib HER-Vaxx data (ASX:IMU)

Jun 2019 09:27 AM

SYDNEY, Australia, 4 June 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced positive data from the ongoing patients in the Phase Ib study of its HER-Vaxx cance...read more
Imugene announce Global Biotechnology and Venture Capital Executive Joins Imugene Board (ASX:IMU)

May 2019 12:13 PM

SYDNEY Australia 20 May 2019: The Board of Imugene Limited today announced the appointment of leading biotechnology executive and entrepreneur Dr Jens Eckstein as a Non-Executive Director, effective 2...read more
Imugene Announces New HER-Vaxx Cancer Vaccine Phase Ib trial data to be presented at the American Society of Clinical Oncology 2019 Annual Meeting (ASX:IMU)

Apr 2019 09:25 AM

SYDNEY, Australia, 29 April 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced updated data from the ongoing patients in the Phase Ib study of its HER-Vaxx canc...read more
Imugene announces Appendix 3X - initial Directors Interest Notice (ASX:IMU)

Apr 2019 05:43 PM

Appendix 3X Initial Director's Interest Notice For further information please download PDF attached:
Imugene announces Leading Global Pharmaceutical Executive Joins Imugene Board (ASX:IMU)

Apr 2019 05:39 PM

SYDNEY Australia 23 April 2019: The Board of Imugene Limited (ASX: IMU) is pleased to announce the appointment of a leading global pharmaceutical executive Dr. Lesley Russell as a Non-Executive Direct...read more
Imugene, Quarterly Activities and Cash Flow Report Quarter ended 31 March 2019 (ASX:IMU)

Apr 2019 12:43 PM

SYDNEY, Australia, 16 April 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce its Quarterly Cash Flow report (Appendix 4C) for the quarter ended 31 Marc...read more
Imugene announces Medical University Vienna presents positive new data on PD-1 mimotope cancer vaccines at the American Association for Cancer Research 2019 Annual Meeting (ASX:IMU)

Apr 2019 08:22 AM

SYDNEY, Australia, 3 April 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, together with the Medical University Vienna today presented positive new data on the PD-1 mimotope...read more

Viewing: 11 - 20 of 51 < Previous | Next >

Media Releases

Latest Company News

Videos

Contact Information

Categories

Newsletter

Recent Companies

Subscribe to our Daily Newsletter?

Daily News